Healthcare - Biotechnology - NASDAQ - US
$ 4.79
-11 %
$ 406 M
Market Cap
-1.95
P/E
INCOME STATEMENT
11.8 M
REVENUE
-223 M
OPERATING INCOME
-200 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Verve Therapeutics, Inc.
| Revenue | 11.8 M |
| Cost Of Revenue | 185 M |
| Gross Profit | -173 M |
| Operating Expenses | 235 M |
| Operating Income | -223 M |
| Other Expenses | -23.1 M |
| Net Income | -200 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| REVENUE | |||||
| Revenue | 11.8 | 1.9 | 0 | 0 | 0 |
| GROSS PROFIT | |||||
| Cost Of Revenue | 184.9 | 6.7 | 3.4 | 1.3 | 0.1 |
| Gross Profit | (173.2) | (4.8) | (3.4) | (1.3) | (0.1) |
| OPERATING INCOME | |||||
| Operating Expenses | 234.9 | 167.6 | 87.1 | 40.6 | 13.6 |
| Selling, General and Administrative Expenses | 49.9 | 37.5 | 18.9 | 5.3 | 2.5 |
| Research and Development Expenses | 184.9 | 130.1 | 68.2 | 35.4 | 11.1 |
| Operating Income | (223.1) | (165.7) | (87.1) | (40.6) | (13.6) |
| PRE-TAX INCOME | |||||
| Interest Income Expense | 0 | 0 | 0 | 0 | 0 |
| Total Other Income | 23.3 | 8.4 | (33.2) | (5.1) | (5.7) |
| Pre-Tax Income | (199.8) | (157.3) | (120.3) | (45.7) | (19.3) |
| NET INCOME | |||||
| Tax Provision | 0.3 | 53 K | (1.7) | (0.2) | (0.3) |
| Net Income | (200.1) | (157.4) | (118.6) | (45.5) | (19.0) |
| EPS | 3.12 | 2.91 | 2.45 | 0.94 | 0.39 |